Levetiracetam in Epileptic Elderly Patients with Chronic Cerebrovascular Disease
Abstract number :
3.179
Submission category :
Clinical Epilepsy-Adult
Year :
2006
Submission ID :
6842
Source :
www.aesnet.org
Presentation date :
12/1/2006 12:00:00 AM
Published date :
Nov 30, 2006, 06:00 AM
Authors :
1Annamaria M. Terracciano, 2Gennaro Barbato, 2Pasquale Alfieri, 2Rossana Arlomede, 1Loredana Nargi, and 2Giacomo Visco
To evaluate efficacy and tolerability of LEV in elderly patients with newly diagnosed seizures and neuroradiologic findings of Chronic Cerebrovascular Disease (previously asymptomatic)., -elderly patients with onset Epilepsy at onset (Partial seizures)
-LEV as Monotherapy.
-Lev commenced at 250mg/die,titrated weekly by 250 mg to the final dose.
-12 months follow-up : visit every two montlhs, seizure diary check,EEG, complete blood sampling,Mini Mental State Examination(MMSE), Short Form Health Survey ( SF12)and caregiver Neuropsychiatric Inventory ( NPI ) questionnaires.
Outcome assessments
-Change in seizure frequency
-Quality of life (by MMSE,SF12 e NPI )
-Tolerability by evaluating LEV-related AEs., 33 patients were included and all of them completed the 12 months study and achieved seizure freedom.
27(81.8%) with LEV dose 1000-1500mg daily.
6 (18.1% ) needed add-on therapy with other AED:Topiramate,Lamotrigine,Oxcarbazepine.
LEV showed no interactions with any concomitant drug used for other patologies(Diabetes Mellitus, Hypertension,Mood Depression,etc)
MMSE ,SF12 and NPI score did not worsen.
31 patients showed AEs during the titration phase: somnolence(n=5), headache(n=23), dizziness(n=2),mental confusion(n=1)., LEV showed god efficacy and tolerability in treatment of Epilepsy in elderly patients with Chronic Cerebrovascular Disease.,
Clinical Epilepsy